STRO - NASDAQ
Sutro Biopharma, Inc.
$24.43
+17%Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotSutro Biopharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Sutro Biopharma, Inc. Cash Flow Statement
STRO • NASDAQ
| Sutro Biopharma, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
-191.1M | -227.5M | -106.8M | -119.2M | -105.5M | -32.1M | -55.7M | -35.3M | -19.7M | 1.7M | |
7.3M | 7.2M | 6.8M | 5.7M | 4.8M | 4.3M | 4.8M | 4.5M | 5M | 5.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 7.2M | -41M | -1.3M | -1.5M | 3M | 80K | |
14M | 24.7M | 24.9M | 26.3M | 23.2M | 11.9M | 10.3M | 2.9M | 1.4M | 968K | |
42.9M | -4.9M | -2.2M | -13.6M | 6.2M | 606K | 193K | -517K | 132K | 98K | |
(0.0) | (17.5M) | (379K) | (0.0) | (103K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-50.4M | 8.9M | -34.4M | 104.4M | -17.6M | -11.5M | -23.3M | 42.6M | -26.9M | -21.7M | |
-177.2M | -191.5M | -111.6M | 3.5M | -81.7M | -67.8M | -65M | 12.7M | -37.1M | -13.2M | |
INVESTING ACTIVITIES | ||||||||||
-1.7M | -3.1M | -4.3M | -7.9M | -15.3M | -7.1M | -3.5M | -1.6M | -3.3M | -4.4M | |
(0.0) | (0.0) | (0.0) | (28.7M) | (0.0) | (0.0) | (47.7M) | (0.0) | (0.0) | (16K) | |
-265M | -461.5M | -460.3M | -216.7M | -248.7M | -130.7M | -196.2M | -81.5M | -14.2M | -52.3M | |
311.7M | 683.1M | 460.7M | 189.5M | 166.7M | 138.4M | 148.6M | 2.8M | 50.1M | 66.3M | |
0.0 | 0.0 | 0.0 | -28.7M | 9K | 89K | -47.7M | 80K | 80K | 16K | |
(45M) | (218.5M) | -3.9M | -35M | -97.3M | (604K) | -51.1M | -80.2M | (32.6M) | (9.6M) | |
FINANCING ACTIVITIES | ||||||||||
376K | 96.5M | 12M | 56.3M | -7K | 251.4M | -327K | 84.4M | 0.0 | 0.0 | |
0.0 | -4.1M | -12.5M | -9.4M | 0.0 | 15M | -5M | 0.0 | 15M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | -7K | (0.0) | -327K | (0.0) | (0.0) | (0.0) | |
-332K | 1.6M | 138.1M | 1.4M | 4.3M | 2.8M | -297K | 1.6M | -362K | 177K | |
44K | 94.1M | 137.6M | 48.3M | 3.3M | 269.2M | -4.2M | 170.8M | 14.6M | 177K | |
CASH FLOW SUMMARY | ||||||||||
-132.2M | 121M | 22M | 16.8M | -175.7M | 202M | -120.3M | 103.3M | 10.2M | -3.4M | |
191.2M | 70.1M | 48.1M | 31.3M | 207M | 5M | 125.3M | 22M | 11.9M | 15.3M | |
59M | 191.2M | 70.1M | 48.1M | 31.3M | 207M | 5M | 125.3M | 22M | 11.9M | |
-178.9M | -194.6M | -115.9M | -4.3M | -97M | -74.9M | -68.5M | 11.1M | -40.4M | -17.5M |
SEC Filings
STRO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
S-3 S-3 N/A | March 23, 2026 | March 23, 2026 | ||
8-K 8-K 2026 N/A | February 10, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 17, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your STRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.